Ozarelix in Medical Technology
Ozarelix in Biological Technology
AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
(NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on
endocrine therapy and oncology, today announced that its partner, Spectrum
Pharmaceuticals (NASDAQ: SPPI ), released Phase 2b results for ozarelix, a
New Report Just Published: World Prostate Cancer Therapeutics Market Report
...or Use in
Late-Stage Prostate Cancer II-62
Protox Gains Clearance from FDA to Conduct Phase I Trial of
Aeterna Zentaris's ozarelix
Phase II Trial Shows Positive Results II-63
Biomira Announces Results of Stimuvax Phase 2 Clinical Study II-64
Cytogen Receives FDA Clearance ...
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
...ls Co., Ltd. (Handok) for the Korean market. Subsequent to quarter end, signing of another agreement with Handok for the commercialization of ozarelix
in BPH for the Korean market; and - Recovery of worldwide rights from Ardana plc (LSE: ARA) for the Growth Hormone Secretagogue (GHS) compound, AE...